FAQ Library

FAQ Library published on March 25, 2021
In this activity, Dr. Baljevic discusses the side-effect profile associated with four-drug regimens.
FAQ Library published on March 23, 2021
In this activity, Dr. Baljevic explains the NCCN guidelines outlining four-drug combinations listed for use in newly diagnosed transplant-eligible patients.
FAQ Library published on January 20, 2021
In this activity, Dr. Raje provides a summary of the KarMMa trial and BB2121 in relapsed/refractory multiple myeloma.
FAQ Library published on January 14, 2021
Dr. Raje explains therapeutic interventions for smoldering multiple myeloma, as well as how to better risk-stratify patients.
FAQ Library published on January 12, 2021
In this activity, Dr. Noopur Raje discusses how to risk-stratify patients with smoldering myeloma and the updated definition of symptomatic myeloma.

Results 1 - 5 of 5